Aspirin thins blood by inhibiting platelet aggregation
Aspirin acts as an antiplatelet agent by inhibiting cyclooxygenase and reducing thromboxane-dependent platelet activation, thereby preventing platelet aggregation.
The retrieved papers consistently confirm that aspirin inhibits cyclooxygenase (COX-1), reduces thromboxane A2, and prevents platelet aggregation (blood thinning via antiplatelet activity). Multiple reviews and experimental studies directly support this claim with no contradictory evidence.
Ewa Miciak-Ławicka, B. Begier-Krasińska, A. Tykarski, Z. Krasiński. Does the timing of aspirin administration influence its antiplatelet effect – review of literature on chronotherapy. 2018. https://doi.org/10.5114/kitp.2018.76479
Paper [0] discusses aspirin's mechanism of action involving the inhibition of cyclooxygenase and thromboxane A2, giving rise to its antiplatelet effect.
See more details
H. Caplain. Enhanced Antiplatelet Effects of Clopidogrel plus Acetylsalicylic Acid Compared with Acetylsalicylic Acid Alone or Combined with Extended-Release Dipyridamole in Healthy Volunteers. 2005. https://doi.org/10.1159/000083885
Paper [1] evaluates acetylsalicylic acid (ASA) as an antiplatelet agent capable of inhibiting arachidonic acid-induced platelet aggregation.
Yudy Tjahjono, Caroline, K. Foe, Srikanth Karnati, S. Ergün, S. Y. Esar, Hendy Wijaya, Wuryanto Hadinugroho, D. Kusindarta, Hevi Wihadmadyatami. Synthesis, Characterization, and Application of 2-((3-(Chloromethyl)-benzoyl)oxy)benzoic Acid: A Review. 2022. https://doi.org/10.1021/acsomega.2c05566
Paper [2] notes that aspirin is widely used due to its additional advantages in preventing platelet aggregation.
Cohen IJ. Delayed Rewarming Thrombocytopenia (DRT): A Temperature-Dependent Platelet Aggregation Disorder.. 2026. https://doi.org/10.3390/hematolrep18030035
Paper [6] states that aspirin blocks the second phase of platelet aggregation.
Di Berardino S, Tacconelli S, Contursi A, Ahfaz HA, Patrignani P. The crucial role of thromboxane A<sub>2</sub> in colorectal cancer development and metastasis: a key target for anticancer therapy.. 2026. https://doi.org/10.3389/fphar.2026.1787936
Paper [11] explains that low-dose aspirin irreversibly and selectively inhibits COX-1 activity in platelets, reducing thromboxane-dependent platelet activation.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt